ESALY News and Press, Eisai Co. Ltd. ADR From 02/28/23

Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration TOKYO, Feb 28, 2023 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that the Biologics License Application (BLA) for lecanemab (brand name ...

Dissolution of Bracco-Eisai Joint Venture TOKYO, Feb 21, 2023 - (JCN Newswire) - Bracco Imaging S.p.A. and Eisai Co., Ltd. announced today that the joint venture regarding the company Bracco-Eisai Co., Ltd. (Ratio of Shares Held: Bracco 51% Eisai 49%), will be dissolved as of March ...

Eisai Co., Ltd. (ESALF) Q3 2022 Earnings Conference Call February 06, 2023 03:15 AM ET Company Participants Tatsuyuki Yasuno - Senior Vice President, Chief Financial Officer, Chief IR Officer Ivan Cheung - Senior Vice President, Global Alzheimer's Disease Officer, Presiden...

The following slide deck was published by Eisai Co., Ltd. in conjunction with their 2022 Q3 earnings call. For further details see: Eisai Co., Ltd. 2022 Q3 - Results - Earnings Call Presentation

Summary Biogen's business focuses on developing and commercializing drugs aimed at treating patients living with neurological and neurodegenerative diseases. The company's total revenue was $2,508.5 million in the third quarter of 2022, down 9.7% from the previous year. The decline ...

A regulatory failure for one drugmaker often represents a key win for another company. That might be the case in the Alzheimer's disease market after a recent U.S. Food and Drug Administration (FDA) decision. Last week, the FDA issued a complete response letter for Eli Lilly 's (NYSE: L...

Summary Anavex 2-73/blarcamesine at high concentrations in early Alzheimer's disease leads to improvements in cognition and activities of daily living that are largely sustained for 148 weeks in most individuals. Alzheon's ALZ-801 reduces cognitive decline in ApoE4 carriers by about the...

EISAI FILES MARKETING AUTHORIZATION APPLICATION FOR ANTI-AMYLOID-BETA PROTOFIBRIL ANTIBODY LECANEMAB FOR EARLY ALZHEIMER'S DISEASE IN JAPAN PR Newswire TOKYO and CAMBRIDGE, Mass. , Jan. 15, 2023 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo , CEO: ...

You can't blame Biogen (NASDAQ: BIIB) investors if they feel a sense of déjà vu. The company, along with its partner, Japanese drugmaker Eisai (OTC: ESALY) , received U.S. Food and Drug Administration (FDA) approval for Alzheimer's disease drug Leqembi (lecanemab-irmb) l...

The US FDA on Friday granted accelerated approval to Biogen ( NASDAQ: BIIB ) and Eisai's ( OTCPK:ESALY ) Leqembi (lecanemab), just the second biologic medicine ever approved for Alzheimer's disease. The therapy is expected to become available around the week of Jan. 23. It com...